{"entity":{"id":"nct03643133","kind":"trial","name":"Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients","aka":[],"tldr":"A phase 2 trial of Mifamurtide in Osteosarcoma, run by UNICANCER, active and no longer recruiting.","summary":"Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients is a phase 2 interventional study registered as NCT03643133 by UNICANCER, with 60 participants planned, started 2018-10-23 and due to reach its primary completion in 2026-09. Interventions recorded: Mifamurtide, EI or M-API regimen depending on patient age. Conditions recorded: Osteosarcoma.\n\nLinked to the drug Mifamurtide because the registry names it among its interventions and Osteosarcoma among its conditions. Registry record only: no result has been read by an editor.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT03643133","url":"https://clinicaltrials.gov/study/NCT03643133"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["osteosarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":["mifamurtide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03643133","phase":"2","setting":"Multicentre, Randomised, Phase 2 Trial of Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients (Metastatic Osteosarcoma at Diagnosis or Localised Disease With Poor Histological Response)","sponsor":"UNICANCER","enrolled":60,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03643133/","neighbours":{"cancer":[{"id":"osteosarcoma","kind":"cancer","name":"Osteosarcoma","route":"/cancers/osteosarcoma/"}],"drug":[{"id":"mifamurtide","kind":"drug","name":"Mifamurtide","route":"/drugs/mifamurtide/"}]}}